The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Parkinson’s Pathway Molecular Data Analysis Program, 2022Investigating the Role of Repeat Expansions and Mitochondrial Dysfunction in Parkinson’s Disease
Study Rationale: Both genetic mutations and exposure to environmental factors contribute to Parkinson’s disease (PD). Genetic risk for someone with PD could be due to multiple genes, different types...
-
Parkinson’s Pathway Molecular Data Analysis Program, 2022Using Data from the LEAPS Project to Improve the Accuracy of Assays that Measure Alpha-synuclein
Study Rationale: The scientific and clinical research community working on Parkinson’s disease (PD) is in need of biomarkers to facilitate the monitoring of disease progression and efficacy of...
-
Parkinson’s Pathway Molecular Data Analysis Program, 2022Resolution of Parkinson-associated Loci and Creation of Predictive Models Using Multi-omic Data Analyses
Study Rationale: Genetic studies have allowed us to understand better the genetic risk of suffering from Parkinson’s disease. However, for most of the findings we do not know the biological meaning or...
-
Parkinson’s Pathway Molecular Data Analysis Program, 2022Mining for Protein Aberrations in Parkinson’s Disease Using Large-Scale Protein Databases
Study Rationale: Deficient clearance of misfolded alpha-synuclein aggregates contributes to the pathology of Parkinson’s disease (PD). But broader disturbances in proteostasis—the balanced production...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Development and Assessment of LRRK2 Type II Inhibitors as Potential Therapeutics for Parkinson’s Disease
Study Rationale: LRRK2 is one of the best validated drug targets for Parkinson’s disease (PD). The LRRK2 inhibitors currently in development — called Type I inhibitors —bind to the closed, or active...
-
Research Grant, 2023Understand Me for Life: Using Noise-augmented Automatic Speech Recognition to Improve Intelligibility in Parkinson’s Disease
Study Rationale: Most people with Parkinson’s disease (PD) develop voice and speech problems at some point during the course of the disease. Such problems, collectively known as the motor speech...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.